Molly Cole

Molly Cole, Ph.D., currently serves as a Senior Associate at Curie.Bio since September 2024. Prior experience includes leading business development and R&D strategy at Shinobi Therapeutics from April 2023 to September 2024, and working as a Research Associate at F-Prime Capital from May 2022 to April 2023, where contributions focused on early-stage biotech investments and collaborations with Shinobi Therapeutics. Academic credentials include a Ph.D. in Immunology from Yale University, where research involved transcriptional regulation in T cell-driven inflammation, and a BA in Cell/Cellular and Molecular Biology from the University of Pennsylvania, during which CAR T-cell constructs were engineered to enhance functional persistence and efficacy.